Delayed cell death resulting from cerebral isch emia is thought to be ultimately due to an excessive rise in free Ca2+ within vulnerable neurons, trig gered by the excitatory neurotransmitter glutamate (Choi, 1988; Siesj6 and Bengtsson, 1989) . Initial op timism that N-methyl-D-aspartate (NMDA) recep tor antagonists might be effective in treating stroke (Gill et a!., 1987) has been tempered by the finding that the most potent of these compounds, MK-801, produced its neuroprotective action by inducing hy pothermia (Buchan and Pulsinelli, 1990; Corbett et a!. , 1990; Nellgard et a!. , 1991) . More recently, the a-amino-3-hydroxy-5-methyl-4-isoxazole propio nate (AMPA) antagonist, NBQX (2,3-dihydroxy-6-nitro-7 -sulfamoyl-benzo(F)quinoxaline), was re-icking an NBQX-induced temperature profile for 28 h postischemia yielded histological protection 4 days later comparable to that of NBQX. However, both the NBQX and temperature simulation groups showed decreased protection after 10-day survival. Our data suggest that a protracted period of subnormal temperature during the postischemic period can obscure the interpretation of pre clinical drug studies. Key Words: Cerebral ischemia NBQX-Glutamate-Non-NMDA-Hypothermia Gerbil.
ported to provide robust protection against neuro nal loss in several animal models, even with post ischemic treatment (Sheardown et aI. , 1990; Buchan et a!. , 1991; Diemer et a!., 1992; Nellgard and Wieloch, 1992; Sheardown et a!. , 1993) . Ac cordingly, it has been concluded that the AMP A receptor has a greater involvement in global isch emic injury than the NMDA receptor, and stroke trials with AMPA antagonists have been suggested .
However, in the majority of studies in which NBQX has provided protection, temperature was not controlled during the postischemic period (Sheardown et ai., 1990; Diemer et a!., 1992; Shear down et a!., 1993) . In view of the fact that many pharmacological studies of cerebral ischemia have been confounded by drug-induced hypothermia, it is essential that putative neuroprotective agents are examined closely to rule out similar interactions with brain temperature. In addition, recent data suggest that the preservation of CAl neurons by several postischemic treatments may not be perma nent (Morse and Davis, 1990; Dietrich et a!., 1993; Colbourne and Corbett, 1994) . Because most phar macological studies, including those with NBQX, have used short survival times (1 week or less), the protection observed with this drug may also be transitory.
Although it has been reported that NBQX does not affect temperature (Sheardown et aI., 1990) , in other reports, a significant decrease in temperature after NBQX administration has been noted when temperature has been monitored for prolonged pe riods (Suga and Nowak, 1992; Nurse and Corbett, 1993) . Using the gerbil two-vessel occlusion model, we compared the postischemic temperature profiles of animals treated with NBQX with those of vehicle controls. To determine whether mild hypothermia contributed to the beneficial effect of NBQX, we gave a third group NBQX but regulated their tem perature from 1 to 24 h postischemia, so that it re sembled the pattern in vehicle-treated animals. In a second experiment we simulated the NBQX tem perature profile, in the absence of drug treatment, and compared the histological outcome with NBQX, at survival times of 4 and 10 days.
METHODS

Brain temperature monitoring
All experimental procedures were carried out accord ing to the animal care guidelines of Memorial University of Newfoundland and the Canadian Council on Animal Care. Brain temperature was recorded on-line from AM transmitter probes inserted through a guide cannula into the dorsal striatum, as described previously (Colbourne and Corbett, 1994; Nurse and Corbett, 1994) . Two days before the administration of NBQX or induction of isch emia, baseline temperature was recorded for 3 h to ensure that readings were within the normal range. The sampling rate for all temperature recordings was three per minute.
Temperature effects of NBQX in normal animals
Two rodent species, Sprague-Dawley rats (n = 4) and gerbils (n = 5), were assessed for their temperature re sponse to NBQX. Two days after initial temperature re cording (see previous section), temperature probes were reinserted into the guide cannula. After baseline record ing for 1 h, NBQX was administered as three separate intraperitoneal injections (3 x 30 mg/kg, i.p.), injections were spaced 15 min apart. The drug was dissolved in NaOH (0.1 M) and diluted in 5.5% glucose. Brain tem perature was monitored for 24 h. NBQX (NNC 07-9202 acid) was donated by Novo-Nordisk, Copenhagen.
Cerebral ischemia
Gerbils were anesthetized with 2% halothane in 30% 02170% N20, and maintained at 1.5% throughout the op erative procedure. The carotid arteries were isolated and occluded for 3 min at normothermia, as described previ ously (Nurse and Corbett, 1994) . Sham-operated animals (n = 3) underwent carotid isolation without ischemia. Brain temperature continued to be monitored postisch emically in unanesthetized animals for up to 30 h. During the initial 60 min of reperfusion, a 60-W lamp was used to maintain normothermia (-37°C), if necessary. Mild post ischemic hyperthermia, which occurs spontaneously, was not prevented. experiment I. Beginning 1 h after carotid occlusion, animals received either vehicle (5.5% glucose, n = 7) or NBQX (30 mg/kg, i.p., n = 16) at 60, 75, and 90 min postischemia. NBQX-treated animals were subdivided into two groups (n = 8 per group): NBQX and NBQX (regulated). Temperature regulation was discontinued in all groups at 60 min reperfusion, except the NBQX (reg ulated) group. In the NBQX (regulated) group, the brain temperature was maintained at the same level observed in the vehicle-treated group using an overhead lamp, with a variable height adjustment, until 24 h postocclusion. Af ter the period of temperature recording (24-30 h), tem perature probes were removed and the animals were re turned to their home cages until 10 days postocclusion.
Experiment II. The aforementioned experiments were repeated to assess vehicle (n = 6) and NBQX (no tem perature regulation, n = 9) treatments at a short survival time of 4 days. A third treatment group was also added, simulating the NBQX-induced temperature profile in the absence of drug treatment (SimTP). The NBQX-induced temperature profile was simulated manually (SimTP) for 28 h postischemia using (a) a fan placed above the cage and/or spraying room temperature water on the animal's back to lower temperature; (b) turning off the fan and/or using a 60-W lamp to elevate temperature. Animals in the SimTP group had survival times of 4 (n = 7) and 10 days (n = 10).
Histological analysis
At either 4 or 10 days postischemia, animals received an overdose of sodium pentobarbital before perfusion fix ation. Brain tissue was placed in 10% phosphate-buffered formalin (pH 7.4) overnight, in situ. The following day, the brain was extracted from the skull and stored in the same fixative. Blocks were dehydrated and embedded in paraffin, sections were cut at 6 f..l m and subsequently stained with hematoxylin and eosin. Three sectors in dor sal CAl (lateral, middle, and medial) were counted in each hemisphere at a level 1.7 mm posterior to bregma. The six sectors were summed to yield a total CAl score. CA I cell counts from six normal animals were pooled with the three sham-operated animals to provide an as sessment of uninjured/normal CAl' CAl counts were per formed by D.C., who was blind to treatment status.
Statistical analysis
Total CAl scores were analyzed with analysis of vari ance (ANOV A), followed by Student-Newman-Keuls post hoc comparisons.
RESULTS
When NBQX (3 x 30 mg/kg, i.p.) was given to normal animals ( Fig. 1) , we observed an initial drop in brain temperature of 2.0°C in gerbils and 3SC in rats. Three to 5 h after drug administration, temper ature partially recovered but to a subnormal level, where it remained for >24 h. The changes recorded in brain temperature were also reflected in rectal temperature, which was sampled periodically in some animals (data not shown).
With postischemic NBQX administration, in the unregulated condition (Fig. 20) , there was also an �2°C decrease in brain temperature below that ob-
... served in the vehicle-treated group (Fig. 2B) , al though the NBQX temperature profile was altered by ischemia (compare Fig. lA and Fig. 2D ). During ischemia, and for the initial 2 h of reperfusion, the brain temperatures of NBQX ( Fig. 2D ) and vehicle ( Fig. 2B ) groups were not different. Thereafter, the temperature of NBQX-treated animals was signifi cantly reduced, 1.0-2.0°C, with a maximal differ ence (-2.0°C) evident 2.5-3 h postischemia. Begin ning 3 h postischemia, temperature gradually de clined in both the NBQX-and vehicle-treated groups, leveling off -I'soC below the starting point at 15 h postischemia. The slopes of the temperature profiles in the NBQX-and vehicle-treated groups were similar, with the NBQX group temperature profile being shifted 1. O-I,SOC below the vehicle group. The brain temperature in the NBQX group was still 1.0-1,SOC lower at 30 h postischemia (Fig.  2D) . In an additional group treated with NBQX, we manually regulated brain temperature until 24 h postischemia (Fig. 2C) mained 1.0-1 SC below the vehicle group until the end of the recording session (Fig. 2C) , which was similar to the temperature recorded in the NBQX, nonregulated group at this time (Fig. 2D) . Virtually all of the variance in histological out come was attributable to these mild differences in postischemic brain temperature during the initial 24 h of reperfusion. The number of viable CAl neurons was inversely related to the mean brain temperature from 0-24 h postischemia (Fig. 3) . ANOV A of the total CAl cell counts for normal, vehicle, NBQX, and NBQX (regulated) groups (experiment l) yielded a significant treatment effect (p < 0.000l). Post hoc comparisons of total CA I counts revealed that the NBQX group had a significantly better his tological outcome compared with both the NBQX (regulated) and vehicle groups (p < 0.0 1), but did have a significant degree of cell loss in comparison to normals (p < 0.01). There was no histological protection achieved with the same dose of NBQX when mild hypothermia was prevented by regulat ing brain temperature for 24 h to resemble the ve hicle group (Fig. 3) .
When protection obtained with NBQX was com pared with the level of protection obtained with a 28-h temperature simulation (Fig. 2E , experiment II) we found that both NBQX and the SimTP treat ment produced substantial savings of CAl neurons, which were not significantly different, when histo logical assessment was made 4 days postisch emically (Fig. 4) 
DISCUSSION
Our results show that NBQX (3 x 30 mg/kg), a dose that has previously been reported to be bene ficial against ischemic injury (Sheardown et aI., 1990; Buchan et aI., 1991; Diemer et aI., 1992) , has a mild hypothermic action that is linearly related to its neuroprotective efficacy. NBQX was ineffective against cerebral ischemia when we regulated tem perature to mimic that of the vehicle group. Fur thermore, simulating the temperature profile in duced by NBQX is sufficient to produce histologi cal preservation of CAl cells. However, there was a significant decline in the protection provided by the SimTP treatment between 4 and 10 days post ischemia (p < 0.01). A similar trend of decreasing efficacy was also observed with NBQX. Although not significant, this trend suggests that necrosis may progress if the survival time is lengthened to several weeks. Although it remains possible that NBQX conveys a neuroprotective effect indepen dent of temperature, we believe that the protection provided by the SimTP treatment decayed at a faster rate than that of NBQX because the duration of mild hypothermia was shorter.
In the present study, the SimTP group was re warmed to normal levels 28 h after ischemia; how ever, it is evident that NBQX-treated animals were still subnormal 30 h postischemically (Fig. 2E vs.  D) . Subsequently, we recorded brain temperature for extended periods (up to 8 days) in animals treated with NBQX (n = 7). NBQX induced a state of mild hypothermia that lasted for �4-5 days (Fig.  5) , thus increasing the period of mild hypothermia by at least 68 h in comparison to the SimTP group. The long-lasting nature of this temperature effect may be due to a lingering precipitate of NBQX that is found in the intraperitoneal cavity (Le Peillet et al., 1992; Buchan et aI., 1993) and internal organs, such as the gallbladder, days to weeks after i.p. administration (S. Nurse and D. Corbett, unpub lished observations). This precipitate might act as a depot, providing sustained release of NBQX in high enough concentrations to produce a hypothermic action for several days. To achieve identical histo logical protection by simulating NBQX-induced hy pothermia, the simulation period may also have to be extended to several days. This was not possible in the present study because temperature was con trolled manually, and maintaining temperature at a slightly subnormal level required constant atten tion. However, recent findings from our laboratory (Colbourne and Corbett, 1994) have shown that 12 h of moderate hypothermia (32°C) produced substan tially less protection than 24 h of hypothermia, with the shorter duration resulting in a profound decline in protective efficacy between 10 and 30-day sur viva l times. It seems that within limits, increasing either the degree or the duration of hypothermia should improve histological outcome. Neverthe less, the present results suggest that mild postisch emic hypothermia, whether drug or nondrug in duced, may not translate to permanent neuropro tection even if the duration of hypothermia is prolonged (i. e., several days). In studies in which survival times have been increased from 7 days to 1 month, neuroprotection with NBQX (3 x 30 mg/kg) has been lost (Li and Buchan, 1995) . The cascade of events resulting in neuronal necrosis may only be Vol. 16, No.3, 1996 temporarily interrupted during the hypothermic pe riod, and once temperature is normalized these pro cesses may resume, albeit at a slower rate. In the present study, and others (Sheardown et aI., 1990) , in which NBQX has been assessed after survival times of only 4 days, histological protection is often indistinguishable from normal cell counts/ratings. According to the findings presented here, the ani mals would have still been mildly hypothermic at this time, which could account for the near total histological preservation. Although the majority of the previous studies us ing NBQX have not regulated temperature during the postischemic period, a study by Buchan et ai. (1991) reported significant histological savings at 7 days when body temperature was regulated post ischemically for 6-8 h. However, as we have shown (Fig. 2C) , the temperature of NBQX-treated ani mals drops a,lmost imm e diately even when temper ature regulation is terminated as late as 24 h. It is also noteworthy that animals treated with NBQX demonstrate hypothermia even when they recover from the mild sedating effects of the drug and begin to show normal ambulation. Recovery of locomo tion is often used as a marker of an animal's ability to thermoregulate after ischemia and a point at which temperature control is typically stopped, this is clearly an incorrect assumption. Because NBQX administration can be delayed for 6-12 h Nurse and Corbett, 1993) and some times 24 h (Sheardown et aI., 1993 ; but see Li and Buchan, 1993) postischemia and still provide neu roprotection, then postischemic temperature regu lation for <24 h is likely to be insufficient if neuro nal protection is due to hypothermia. The severity of the ischemia will probably determine the length of time that is necessary to regulate postischemic temperature and prevent hypothermia from con founding histological outcome. For example, after 5 min of ischemia, which produces >95% CAl cell loss in our model, we have found NBQX treatment to be ineffective if administration is delayed until 6 h after reperfusion (Nurse and Corbett, 1993) . Therefore, with severe ischemia, if NBQX is given within the first few hours of reperfusion then a 6-8-h period of temperature regulation would prob ably suffice. However, after 3 min of ischemia, which produces �85% CAl neuronal loss in our model, treatment can be delayed for at least 6 h and provide histological protection (data not shown). However, the protection was correlated with the level of hypothermia induced, and no histological protection was found after the 6-h delayed admin istration if temperature was regulated from 6 to 24 h postischemia (Nurse and Corbett, 1993) . In models where CAl cell loss is �80% or less (Sheardown et al., 1993) , temperature regulation may need to be continued beyond 24 h to prevent a confounding effect of hypothermia.
This study also helps to reconcile some of the discrepancies between in vivo and cell culture mod els of ischemia and glutamate toxicity. Many in vivo studies comparing the efficacy of NMDA and AMP A glutamate antagonists in global ischemia have found AMP A antagonists to offer considerably greater levels of neuroprotection (Nellgard and Wieloch, 1992; Buchan et al., 1993; Sheardown et al., 1993; Lippert et al., 1994) . In contrast, cell cul ture studies have either found no neuroprotective effects with AMP A antagonists alone (Kaku et al., 1991) , or in cases in which AMP A antagonists were effective the protection was not as great as that pro vided by NMDA antagonists (Lippert et al., 1994) . However, both in vitro (Shuaib et al., 1993; Bruno et al., 1994) and in vivo (Busto et al., 1987; Dietrich et al., 1993; Coimbra and Wieloch, 1994; Colbourne and Corbett, 1994; Nurse and Corbett, 1994 ) studies have demonstrated dramatic protection with hypo thermia. It is important to emphasize that the level of postischemic hypothermia induced by NBQX is milder than that in previous studies (Busto et al., 1989; Dietrich et al., 1993; Coimbra and Wieloch, 1994; Corbett, 1994, 1995) using de liberate hypothermic manipulations (e.g., 32-34°C). These results demonstrate the necessity of careful postischemic temperature assessment in pharmaco logical studies of cerebral ischemia because differ ences of only 1.0-2.0°C, if prolonged, can signifi cantly affect outcome. Furthermore, this study raises important questions about the wisdom of conducting costly clinical trials based on current drug studies that are likely confounded by similar temperature effects and short survival times.
